Cargando…

MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia

We identified mutations in the IL7Ra gene or in genes encoding the downstream signaling molecules JAK1, JAK3, STAT5B, N-RAS, K-RAS, NF1, AKT and PTEN in 49% of patients with pediatric T-cell acute lymphoblastic leukemia (T-ALL). Strikingly, these mutations (except RAS/NF1) were mutually exclusive, s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Canté-Barrett, K, Spijkers-Hagelstein, J A P, Buijs-Gladdines, J G C A M, Uitdehaag, J C M, Smits, W K, van der Zwet, J, Buijsman, R C, Zaman, G J R, Pieters, R, Meijerink, J P P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5240021/ https://www.ncbi.nlm.nih.gov/pubmed/27174491 http://dx.doi.org/10.1038/leu.2016.83

Ejemplares similares

Recurrent NR3C1 Aberrations at First Diagnosis Relate to Steroid Resistance in Pediatric T-Cell Acute Lymphoblastic Leukemia Patients
por: van der Zwet, Jordy C. G., et al.
Publicado: (2020)

IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study
por: Li, Yunlei, et al.
Publicado: (2016)

STAT5 does not drive steroid resistance in T-cell acute lymphoblastic leukemia despite the activation of BCL and BCLXL following glucocorticoid treatment
por: van der Zwet, Jordy C.G., et al.
Publicado: (2022)

BIM mediates synergistic killing of B-cell acute lymphoblastic leukemia cells by BCL-2 and MEK inhibitors
por: Korfi, K, et al.
Publicado: (2016)

Selective Targeting of CTNNB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs
por: Uitdehaag, Joost C. M., et al.
Publicado: (2015)

Lentiviral gene transfer into human and murine hematopoietic stem cells: size matters
por: Canté-Barrett, Kirsten, et al.
Publicado: (2016)

Influence of bisphosphonates or recombinant human parathyroid hormone on in vitro sensitivity of acute lymphoblastic leukemia cells to chemotherapy
por: de Winter, Demi T.C., et al.
Publicado: (2022)

The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition
por: Haagensen, E J, et al.
Publicado: (2012)

MEF2C opposes Notch in lymphoid lineage decision and drives leukemia in the thymus
por: Canté-Barrett, Kirsten, et al.
Publicado: (2022)

Structural insights into human Arginase-1 pH dependence and its inhibition by the small molecule inhibitor CB-1158
por: Grobben, Yvonne, et al.
Publicado: (2019)

Stable aneuploid tumors cells are more sensitive to TTK inhibition than chromosomally unstable cell lines
por: Libouban, Marion A.A., et al.
Publicado: (2017)

Loss of CD44(dim) Expression from Early Progenitor Cells Marks T-Cell Lineage Commitment in the Human Thymus
por: Canté-Barrett, Kirsten, et al.
Publicado: (2017)

High Prevalence of Constitutional Mismatch Repair Deficiency in a Pediatric T-cell Lymphoblastic Lymphoma Cohort
por: Kroeze, Emma, et al.
Publicado: (2021)

Combined inhibition of MEK and Plk1 has synergistic anti-tumor activity in NRAS mutant melanoma
por: Posch, C, et al.
Publicado: (2015)

Synergistic killing of human leukaemic lymphoblasts by glucocorticoids and cytosine arabinoside.
por: Gledhill, R. M., et al.
Publicado: (1983)

MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations
por: Kerstjens, Mark, et al.
Publicado: (2016)

Inhibiting MEK in MAPK pathway-activated myeloma
por: Heuck, C J, et al.
Publicado: (2016)

Synergistic action of dual IGF1/R and MEK inhibition sensitizes childhood acute lymphoblastic leukemia (ALL) cells to cytotoxic agents and involves downregulation of STAT6 and PDAP1
por: Weston, Victoria J., et al.
Publicado: (2018)

Mononuclear cells contaminating acute lymphoblastic leukaemic samples tested for cellular drug resistance using the methyl-thiazol-tetrazolium assay.
por: Kaspers, G. J., et al.
Publicado: (1994)

Phosphoproteomic profiling of T cell acute lymphoblastic leukemia reveals targetable kinases and combination treatment strategies
por: Cordo’, Valentina, et al.
Publicado: (2022)

Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia
por: Degryse, S, et al.
Publicado: (2018)

Synergistic effects of BET and MEK inhibitors promote regression of anaplastic thyroid tumors
por: Zhu, Xuguang, et al.
Publicado: (2018)

A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma
por: Papayannidis, C, et al.
Publicado: (2015)

Comparison of the Cancer Gene Targeting and Biochemical Selectivities of All Targeted Kinase Inhibitors Approved for Clinical Use
por: Uitdehaag, Joost C. M., et al.
Publicado: (2014)

Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia
por: Degryse, S., et al.
Publicado: (2018)

An adequate human T cell repertoire from a single T cell progenitor: Lessons from an experiment of nature
por: Canté-Barrett, Kirsten, et al.
Publicado: (2020)

Different types of non-P-glycoprotein mediated multiple drug resistance in children with relapsed acute lymphoblastic leukaemia.
por: Pieters, R., et al.
Publicado: (1992)

Venetoclax and dinaciclib elicit synergistic preclinical efficacy against hypodiploid acute lymphoblastic leukemia
por: Pariury, Holly, et al.
Publicado: (2023)

Risk factors for MEK-associated retinopathy in patients with advanced melanoma treated with combination BRAF and MEK inhibitor therapy
por: Booth, Andrew E. C., et al.
Publicado: (2020)

TGFβ engages MEK/ERK to differentially regulate benign and malignant pancreas cell function
por: Principe, D R, et al.
Publicado: (2017)

PTEN deletion drives acute myeloid leukemia resistance to MEK inhibitors
por: Smith, Amanda M., et al.
Publicado: (2019)

A Molecular Test for Quantifying Functional Notch Signaling Pathway Activity in Human Cancer
por: Canté-Barrett, Kirsten, et al.
Publicado: (2020)

Cytotoxic Effects of Vitamin A in Combination with Vincristine, Daunorubicin and 6‐Thioguanine upon Cells from Lymphoblastic Leukemic Patients
por: Pieters, Rob, et al.
Publicado: (1991)

Mechanisms of suppression of cell growth by dual inhibition of ALK and MEK in ALK-positive non-small cell lung cancer
por: Shrestha, N., et al.
Publicado: (2019)

PKCζ and PKMζ are overexpressed in TCF3-rearranged paediatric acute lymphoblastic leukaemia and are associated with increased thiopurine sensitivity
por: Hartsink-Segers, S A, et al.
Publicado: (2015)

Synergistic inhibition of MEK and reciprocal feedback networks for targeted intervention in malignancy
por: Li, Yanan, et al.
Publicado: (2019)

Prognostic factors for survival after allogeneic transplantation in acute lymphoblastic leukemia
por: Greil, C., et al.
Publicado: (2020)

Erratum: PTEN deletion drives acute myeloid leukemia resistance to MEK inhibitors
por: Smith, Amanda M., et al.
Publicado: (2020)

Blockade of inhibitors of apoptosis (IAPs) in combination with tumor-targeted delivery of tumor necrosis factor-α leads to synergistic antitumor activity
por: Yuan, Z, et al.
Publicado: (2013)

MEK Inhibitor U0126 Reverses Protection of Axons from Wallerian Degeneration Independently of MEK–ERK Signaling
por: Evans, Catherine, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_8jkjlqjuic1h5p8shscpd1uh09